When National Public Radio’s Science Friday devotes most of a program to a psychiatric study, it must be newsworthy. The STAR*D study got this special treatment recently, with Ira Flato interviewing John Rush about the ins and outs of the NIMH-funded project.
Read More
Because the first results from STAR*D make antidepressants look less powerful than we might have hoped, researchers have emphasized another aspect of the study – namely, that it represents a system that allows us to bring research techniques into our practices. A review of the STAR*D treatment manual is a useful exercise.
Read More
Dr. Rush, thanks for agreeing to help us understand the STAR*D trial. You were the overall principal investigator of what I believe was the largest study in history comparing different antidepressants. Looking at the first set of results, are you encouraged by the findings?
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
